The earlier,the better?A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer

作     者：Fajiu Li Ying Chen Juanjuan Wu Chenghong Li Shi Chen Ziyang Zhu Wei Qin Min Liu Bingzhu Hu Shuang Liu Wenzhao Zhong 

作者机构：Department of Pulmonary and Critical Care MedicineAffiliated Hospital of Jianghan UniversityWuhanHubeiChina Guangdong Provincial Key Laboratory of Translational Medicine in Lung CancerGuangdong Lung Cancer InstituteGuangdong Provincial People's HospitalGuangdong Academy of Medical SciencesGuangzhouGuangdongChina 

出 版 物：《Chronic Diseases and Translational Medicine》 (慢性疾病与转化医学（英文版）)

年 卷 期：2022年第8卷第2期

页      面：100-111页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：immune checkpoint inhibitors neoadjuvant treatment non-small-cell lung cancer 

摘      要：Immune checkpoint inhibitors(ICIs)have revolutionized the approach to advanced and locally advanced non-small-cell lung cancer(NSCLC).Antibodies blocking inhibitory immune checkpoints,such as programmed death 1(PD-1)and its ligand(PD-L1),have remarkable antitumor efficacy and have been approved as a standard first-or second-line treatment in non-oncogene-addicted advanced *** successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long-term overall survival and curative *** this review,we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung *** reviewed the early-phase results from neoadjuvant clinical trials,the landscape of the majority of ongoing phase III trials,and discuss the prospects of ICIs as a curative therapy for resectable lung *** also summarized the potential biomarkers and beneficiaries involved in the current study,as well as the remaining unresolved challenges for neoadjuvant immunotherapy.